drugset / Trial / NCT06783647
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
Recruiting
230 enrolled
Nanjing Leads Biolabs Co.,Ltd
Sun Yat-Sen University Cancer Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Timeline
- Start
- 2025-06-11
- Primary completion
- 2026-12-24
- Completion
- 2026-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | LBL-024 | Unknown | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |